Inflammatory mediators of hepatic steatosis

Mediators of Inflammation

Volumn 2010, Issue , 2010, Pages

  Bujanda, Luis ^a   Hijona, Elizabeth ^a   Hijona, Lander ^b   Arenas, Juan I ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADIPONECTIN; ALLOPURINOL; ALPHA TOCOPHEROL; BETAINE; BEZAFIBRATE; CYTOCHROME P450 2E1; EZETIMIBE PLUS SIMVASTATIN; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LOSARTAN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; RESISTIN; ROSIGLITAZONE; SRT 1720; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; AUTACOID;

ADIPOCYTE; APPETITE; CYTOKINE PRODUCTION; DYSLIPIDEMIA; ENDOTOXEMIA; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEREDITY; HIPPOCAMPUS; HUMAN; HYPERINSULINISM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; ANIMAL; FATTY LIVER; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; FATTY LIVER; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; OBESITY; OXIDATIVE STRESS; RISK FACTORS;

EID: 77951698512     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2010/837419     Document Type: Review

References (107)

1. Castellano G., Esteatohepatitis no alcohlica Gastroenterol Hepatol 1999 22 13 19
2. McCullough A. J., Update on nonalcoholic fatty liver disease Journal of Clinical Gastroenterology 2002 34 3 255 262 (Pubitemid 34177381)
3. Adams L. A., Lymp J. F., Sauver J. St., The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 2005 129 1 113 121 (Pubitemid 41002048)
4. Garca M. C., Non-alcoholic steatohepatitis Journal of Gastroenterology and Hepatology 2001 24 395 402
5. Reddy J. K., Rao M. S., Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation American Journal of Physiology 2006 290 5 G852 G858
6. Schwimmer J. B., Behling C., Newbury R., Histopathology of pediatric nonalcoholic fatty liver disease Hepatology 2005 42 3 641 649 (Pubitemid 41233657)
7. Sols Herruzo J. A., Garca R., Prez Carreras M., Muoz Yage M. T., Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction Revista Espanola de Enfermedades Digestivas 2006 98 11 844 874 (Pubitemid 350259114)
8. Wei Y., Rector R. S., Thyfault J. P., Ibdah J. A., Nonalcoholic fatty liver disease and mitochondrial dysfunction World Journal of Gastroenterology 2008 14 2 193 199 (Pubitemid 351314298)
9. George J., Liddle C., Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets Molecular Pharmaceutics 2008 5 1 49 59 (Pubitemid 351300034)
10. Preiss D., Sattar N., Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations Clinical Science 2008 115 5-6 141 150
11. Falck-Ytter Y., Younossi Z. M., Marchesini G., McCullough A. J., Clinical features and natural history of nonalcoholic steatosis syndromes Seminars in Liver Disease 2001 21 1 17 26 (Pubitemid 32240483)
12. Prez-Carreras M., Castellano G., Gutirrez M. A., Esteatohepatitis no alcohlica: una entidad no tan infrecuente Revista Espaola de Enfermedades Digestivas 1998 90 240 241
13. Piol V., Bessa X., Bruguera M., Rods J., Esteatosis y esteatohepatitis no alcohlica. Anlisis comparativo Gastroenterologia y Hepatologia 2000 23 2 57 61
14. Castellano G., The natural history of hepatitis C virus infection Nephrology Dialysis Transplantation 2000 15 19 23 (Pubitemid 32149501)
15. Duvnjak M., Leroti I., Bari N., Tomai V., Juki L. V., Velagi V., Pathogenesis and management issues for non-alcoholic fatty liver disease World Journal of Gastroenterology 2007 13 34 4539 4550 (Pubitemid 47455230)
16. Harrison S. A., Kadakia S., Lang K. A., Schenker S., Nonalcoholic steatohepatitis: what we know in the new millennium American Journal of Gastroenterology 2002 97 11 2714 2724 (Pubitemid 35265419)
17. Lazo M., Clark J. M., The epidemiology of nonalcoholic fatty liver disease: a global perspective Seminars in Liver Disease 2008 28 4 339 350
18. Targher G., Bertolini L., Padovani R., Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease Diabetic Medicine 2006 23 4 403 409
19. Fehr J., Nmeth E., Lengyel G., Non-alcoholic steatohepatitis (NASH) Archives of Medical Science 2005 1 1 37 47
20. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S., Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study Hepatology 2005 42 1 44 52
21. Dembowski E., Davidson M. H., Role of statin therapy in the management of patients with the metabolic syndrome Archives of Medical Science 2007 3 4 S102 S108
22. Angulo P., Medical progress: nonalcoholic fatty liver disease The New England Journal of Medicine 2002 346 16 1221 1231 (Pubitemid 34984585)
23. Reaven G. M., Syndrome X: 6 years later Journal of Internal Medicine 1994 236 736 13 22
24. Moreno D., Castellano G., El hgado en la obesidad Journal of Gastroenterology and Hepatology 1993 16 550 558
25. Youssef W. I., McCullough A. J., Steatohepatitis in obese individuals Baillieres Best Practice and Research in Clinical Gastroenterology 2002 16 5 733 747 (Pubitemid 38001860)
26. Garca-Monzn C., Martn-Prez E., Iacono O. L., Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated obesity Journal of Hepatology 2000 33 5 716 724
27. Adams L. A., Knuiman M. W., Divitini M. L., Olynyk J. K., Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption Journal of Gastroenterology and Hepatology 2008 23 7 1089 1093
28. Berthoud H. R., Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance Obesity 2006 14 supplement 5 197S 200S
29. Prez-Rodrigo C., Bartrina J. A., Majem L. S., Moreno B., Rubio A. D., Epidemiology of obesity in Spain. Dietary guidelines and strategies for prevention International Journal for Vitamin and Nutrition Research 2006 76 4 163 171 (Pubitemid 46173281)
30. Allender S., Rayner M., The burden of overweight and obesity-related ill health in the UK Obesity Reviews 2007 8 5 467 473 (Pubitemid 47283944)
31. bel T., Fehr J., Non-alcoholic fatty liver disease and cardiovascular risk Hungarian Medical Journal 2008 2 509 518
32. Sookoian S., Pirola C. J., Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review Journal of Hepatology 2008 49 4 600 607
33. Kumar A., Cannon C. P., The current role of statins in acute coronary syndrome Archives of Medical Science 2007 3 4 S115 S125
34. Day C. P., James O. F. W., Steatohepatitis: a tale of two Hits? Gastroenterology 1998 114 4 842 845
35. Neuschwander-Tetri B.A., Caldwell S. H., Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 2003 37 5 1202 1219
36. Chitturi S., Farrell G. C., Etiopathogenesis of nonalcoholic steatohepatitis Seminars in Liver Disease 2001 21 1 27 41
37. James O., Day C., Non-alcoholic steatohepatitis: another disease of affluence The Lancet 1999 353 9165 1634 1636
38. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K. S., Apolipoprotein synthesis in nonalcoholic steatohepatitis Hepatology 2002 35 4 898 904
39. Sanyal A. J., Campbell-Sargent C., Mirshahi F., Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 2001 120 5 1183 1192
40. Yang S. Q., Lin H. Z., Lane M. D., Clemens M., Diehl A. M., Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis Proceedings of the National Academy of Sciences of the United States of America 1997 94 6 2557 2562
41. Oneta C. M., Dufour J.-F., Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations Swiss Medical Weekly 2002 132 35-36 493 505
42. Macas-Rodrguez R. U., Torre A., Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overview Revista de Investigacion Clinica 2009 61 2 161 172
43. Pagano G., Pacini G., Musso G., Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association Hepatology 2002 35 2 367 372
44. Prez-Carreras M., Vargas C., Castellano G., Metabolismo de la glucosa/insulina en la esteatohepatitis no alcohlica Journal of Gastroenterology and Hepatology 2001 24 supplement 94 100
45. Fabbrini E., Mohammed B. S., Magkos F., Korenblat K. M., Patterson B. W., Klein S., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease Gastroenterology 2008 134 2 424 431
46. Kahn B. B., Flier J. S., Obesity and insulin resistance Journal of Clinical Investigation 2000 106 4 473 481
47. Eto K., Yamashita T., Matsui J., Terauchi Y., Noda M., Kadowaki T., Genetic manipulations of fatty acid metabolism in -cells are associated with dysregulated insulin secretion Diabetes 2002 51 supplement 3 S414 S420
48. Haque M., Sanyal A. J., The metabolic abnormalities associated with non-alcoholic fatty liver disease Baillieres Best Practice and Research in Clinical Gastroenterology 2002 16 5 709 731
49. Mannaerts G. P., Van Veldhoven P. P., Casteels M., Peroxisomal Lipid Degradation via -and -oxidation in Mammals Cell Biochemistry and Biophysics 2000 32 73 87
50. Reddy J. K., Hashimoto T., Peroxisomal -oxidation and peroxisome proliferatoractivated receptor : an adaptive metabolic system Annual Review of Nutrition 2001 21 193 230
51. Fong D. G., Nehra V., Lindor K. D., Buchman A. L., Metabolic and nutritional considerations in nonalcoholic fatty liver Hepatology 2000 32 1 3 10
52. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K. S., Apolipoprotein synthesis in nonalcoholic steatohepatitis Hepatology 2002 35 4 898 904
53. Valenti L., Fracanzani A. L., Dongiovanni P., Tumor necrosis factor promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease Gastroenterology 2002 122 2 274 280
54. Fernndez-Real J.-M., Broch M., Vendrell J., Tumour necrosis factor- (TNF- ) polymorphisms -857C/A and -863C/A are associated with TNF- secretion from human adipose tissue. Diabetologia 44: 654-655 Diabetologia 2002 45 1 149 150
55. Crespo J., Cayoen A., Fernendez-Gil P., Gene expression of tumor necrosis factor and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients Hepatology 2001 34 6 1158 1163
56. Li N., Klaassen C. D., Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (Oatp4; Oatplb2; Slc21a10) by lipopolysaccharide Molecular Pharmacology 2004 66 3 694 701
57. Hughes D. E., Stolz D. B., Yu S., Elevated hepatocyte levels of the Forkhead box A2 (HNF-3 ) transcription factor cause postnatal steatosis and mitochondrial damage Hepatology 2003 37 6 1414 1424
58. Morral N., Edenberg H. J., Witting S. R., Altomonte J., Chu T., Brown M., Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liver Journal of Lipid Research 2007 48 7 1499 1510
59. Weltman M. D., Farrell G. C., Hall P., Ingelman-Sundberg M., Liddle C., Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis Hepatology 1998 27 1 128 133
60. Rao M., Reddy J. K., Peroxisomal beta-oxidation and steatohepatitis Seminars in Liver Disease 2001 21 43 55
61. Prez-Carreras M., del Hoyo P., Martin M. A., Activity of the mitochondrial respiratory chain enzymes is increased in the liver of patients with nonalcoholic steatohepatitis Hepatology 1999 30 supplement 379A
62. Browning J. D., Horton J. D., Molecular mediators of hepatic steatosis and liver injury Journal of Clinical Investigation 2004 114 2 147 152
63. Pessayre D., Mansouri A., Fromenty B., Nonalcoholic steatosis and steatohepatitis V. mitochondrial dysfunction in steatohepatitis American Journal of Physiology 2002 282 2 45-2 G193 G199
64. Pessayre D., Berson A., Fromenty B., Mansouri A., Mitochondria in steatohepatitis Seminars in Liver Disease 2001 21 1 57 69
65. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J. M., Positional cloning of the mouse obese gene and its human homologue Nature 1994 372 6505 425 432
66. Halaas J. L., Boozer C., Blair-West J., Fidahusein N., Denton D. A., Friedman J. M., Physiological response to long-term peripheral and central leptin infusion in lean and obese mice Proceedings of the National Academy of Sciences of the United States of America 1997 94 16 8878 8883
67. Singh A., Wirtz M., Parker N., Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels Proceedings of the National Academy of Sciences of the United States of America 2009 106 31 13100 13105
68. Tsochatzis E. A., Papatheodoridis G. V., Archimandritis A. J., Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy Mediators of inflammation 2009 2009 8
69. Andreelli F., Foretz M., Knauf C., Liver adenosine monophosphate- activated kinase- 2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin Endocrinology 2006 147 5 2432 2441
70. Rabe K., Lehrke M., Parhofer K. G., Broedl U. C., Adipokines and insulin resistance Molecular Medicine 2008 14 11-12 741 751
71. Marra F., Bertolani C., Adipokines in liver diseases Hepatology 2009 50 3 957 969
72. Myers M. G., Cowley M. A., Munzberg H., Mechanisms of leptin action and leptin resistance Annual Review of Physiology 2008 70 537 556
73. Uygun A., Kadayifci A., Yesilova Z., Serum leptin levels in patients with nonalcoholic steatohepatitis American Journal of Gastroenterology 2000 95 12 3584 3589
74. Chitturi S., Farrell G., Frost L., Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002 36 2 403 409
75. Tilg H., Moschen A. R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity Nature Reviews Immunology 2006 6 10 772 783
76. Xu A., Wang Y., Keshaw H., Xu L. Y., Lam K. S. L., Cooper G. J. S., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice Journal of Clinical Investigation 2003 112 1 91 100
77. Masaki T., Chiba S., Tatsukawa H., Adiponectin protects LPS-induced liver injury through modulation of TNF- in KK-Ay obese mice Hepatology 2004 40 1 177 184
78. Hui J. M., Hodge A., Farrell G. C., Kench J. G., Kriketos A., George J., Beyond insulin resistance in NASH: TNF- or adiponectin? Hepatology 2004 40 1 46 54
79. Bugianesi E., Pagotto U., Manini R., Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity Journal of Clinical Endocrinology and Metabolism 2005 90 6 3498 3504
80. Bajaj M., Suraamornkul S., Piper P., Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients Journal of Clinical Endocrinology and Metabolism 2004 89 1 200 206 (Pubitemid 38183882)
81. Qi L., Doria A., Manson J. E., Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes Diabetes 2006 55 5 1512 1516
82. Franckhauser S., Elias I., Rotter Sopasakis V., Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice Diabetologia 2008 51 7 1306 1316
83. Wieckowska A., Papouchado B. G., Li Z., Lopez R., Zein N. N., Feldstein A. E., Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis American Journal of Gastroenterology 2008 103 6 1372 1379
84. Singhal N. S., Patel R. T., Qi Y., Lee Y.-S., Ahima R. S., Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice American Journal of Physiology 2008 295 2 E331 E338
85. Day C. P., Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002 50 5 585 588
86. McCullough A. J., Update on nonalcoholic fatty liver disease Journal of Clinical Gastroenterology 2002 34 3 255 262
87. Haukeland J. W., Konopski Z., Eggesb H. B., Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial Scandinavian Journal of Gastroenterology 2009 44 7 853 860
88. Garca-Monzn C., Pons F., Planas R., Salmern J., Enfermedad heptica grasa no alcohlica Enfermedades hepticas. Consejos prcticos 2007 Barcelona, Spain Asociacin Espaola Para el Estudio del Hgado 55 61
89. Suzuki I., Yamauchi T., Onuma M., Nozaki S., Allopurinol, an inhibitor of uric acid synthesiscan it be used for the treatment of metabolic syndrome and related disorders? Drugs of Today 2009 45 5 363 378
90. Masterton G. S., Plevris J. N., Hayes P. C., Omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. to appear in Alimentary Pharmacology Therapeutics
91. Nakamuta M., Fujino T., Yada R., Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPAR -MDR3 pathway International Journal of Clinical Pharmacology and Therapeutics 2010 48 1 22 28
92. bel T., Fehr J., Dinya E., Eldin M. G., Kovcs A., Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease Medical Science Monitor 2009 15 12 MS6 MS11
93. Yamazaki Y., Usui I., Kanatani Y., Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice American Journal of Physiology 2009 297 5 E1179 E1186
94. Vilar Gomez E., Rodriguez De Miranda A., Gra Oramas B., Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease Alimentary Pharmacology and Therapeutics 2009 30 10 999 1009
95. Witek R. P., Stone W. C., Karaca F. G., Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis Hepatology 2009 50 5 1421 1430
96. Yu H.-Y., Wang B.-L., Zhao J., Yao X.-M., Gu Y., Li Y., Protective effect of bicyclol on tetracycline-induced fatty liver in mice Toxicology 2009 261 3 112 118
97. Rosselli M. S., Burgueo A. L., Carabelli J., Schuman M., Pirola C. J., Sookoian S., Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model Atherosclerosis 2009 206 1 119 126
98. You M., Considine R. V., Leone T. C., Kelly D. P., Crabb D. W., Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice Hepatology 2005 42 3 568 577
99. Gustafson B., Hammarstedt A., Andersson C. X., Smith U., Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 11 2276 2283
100. Schenk S., Saberi M., Olefsky J. M., Insulin sensitivity: modulation by nutrients and inflammation Journal of Clinical Investigation 2008 118 9 2992 3002
101. Shoelson S. E., Herrero L., Naaz A., Obesity, inflammation, and insulin resistance Gastroenterology 2007 132 6 2169 2180
102. Tacke F., Luedde T., Trautwein C., Inflammatory pathways in liver homeostasis and liver injury Clinical Reviews in Allergy and Immunology 2009 36 1 4 12
103. Dong B., Saha P. K., Huang W., Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease Proceedings of the National Academy of Sciences of the United States of America 2009 106 44 18831 18836
104. Zheng L., Lv G.-C., Sheng J., Yang Y.-D., Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR- expression, a novel mechanism for the pathogenesis of NAFLD Journal of Gastroenterology and Hepatology 2010 25 1 156 163
105. Sato R., SREBPs: protein interaction and SREBPs FEBS Journal 2009 276 3 622 627
106. Yoon M., The role of PPAR in lipid metabolism and obesity: focusing on the effects of estrogen on PPAR actions Pharmacological Research 2009 60 3 151 159
107. Bell L. N., Theodorakis J. I., Vuppalanchi R., Serum proteomics and biomarker discovery across the spectrum of non-alcoholic fatty liver disease Hepatology 2010 51 111 120